



Recombinant Protein Technical Manual  
Recombinant Mouse FABP4/A-FABP/AFABP Protein  
(His Tag)  
RPES0467

#### Product Data:

**Product SKU:** RPES0467

**Size:** 20µg

**Species:** Mouse

**Expression host:** E. coli

**Uniprot:** NP\_077717.1

#### Protein Information:

**Molecular Mass:** 15.5 kDa

**AP Molecular Mass:** 15 kDa

**Tag:** N-His

**Bio-activity:**

**Purity:** > 95 % as determined by SDS-PAGE

**Endotoxin:** Please contact us for more information.

**Storage:** Lyophilized proteins are stable for up to 12 months when stored at -20 to -80°C. Reconstituted protein solution can be stored at 4-8°C for 2-7 days. Aliquots of reconstituted samples are stable at < -20°C for 3 months.

**Shipping:** This product is provided as lyophilized powder which is shipped with ice packs.

**Formulation:** Lyophilized from sterile 50mM tris, 0.2 M NaCl, pH 7.5

**Reconstitution:** Please refer to the printed manual for detailed information.

**Application:**

**Synonyms:** 422/aP2;ALBP/Ap2;Ap2;Lbpl

## Immunogen Information:

**Sequence:** Cys2-Ala132

## Background:

Fatty acid-binding protein, adipocyte, also known as Adipocyte-type fatty acid-binding protein, Fatty acid-binding protein 4, Adipocyte lipid-binding protein, and FABP4, is a cytoplasm protein which belongs to the calycin superfamily and Fatty-acid binding protein (FABP) family. In familial combined hyperlipidemia (FCHL), FABP4 correlated to body mass index (BMI), waist circumference and homeostasis model assessment (HOMA) index. FABP4 levels were associated with triglyceride-rich lipoproteins. In humans serum FABP4 levels correlate significantly with features of PCOS. It appears to be a determinant of atherogenic dyslipidemia. FABP4 pathway mediates the sebaceous gland hyperplasia in keratinocyte-specific Pten-null mice. FABP4 concentration significantly increased with an increasing of MS features and was strongly correlated with body-mass index, triglycerides, HDL-cholesterol concentrations and blood pressure. Patients in the highest quartile of FABP4 presented a six-fold increased odds ratio for MS and a three-fold increased odds for LD, adjusted by age, sex, body-mass index and the antiretroviral therapy. FABP4 is a strong plasma marker of metabolic disturbances in HIV-infected patients, and therefore, could serve to guide therapeutic intervention in this group of patients.